Ambu halves pipeline to put quality over quantity

Ambu CEO Britt Meelby Jensen has scrapped half the Danish medtech company’s development projects under a new strategy, which will also halve future launches – but she won’t say which ones are out.

Though Ambu's new strategy promises to discontinue a number of products, markets, and customer segments, Britt Meelby Jensen does not name any specific casualties. | Photo: Ambu/PR

Under Ambu’s new strategy, Zoom In, the company will concentrate on fewer products, fewer customers, and fewer markets going forward, says Chief Executive Officer Britt Meelby Jensen. Half of the current development projects have been shelved.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs